NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01664975,Treatment of Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT01664975,,COMPLETED,"The purpose of this study is to evaluate the efficacy and safety of GDPT regiment (gemcitabineï¼Œcisplatin,Prednisone ,Thalidomide

) for patients with Peripheral T-cell lymphoma.",YES,Peripheral T-cell Lymphoma,DRUG: GDPT regimen|DRUG: CHOP regimen,"Progression-free Survival, up to end of follow-up-phase (approximately 24 months)","Response Rate, 21 days(3 weeks) for one cycle,Efficacy was evaluated every two cycles, every 6 weeks,up to completion of treatment(approximately 18 weeks )|Overall Survival, up to the date of death (approximately 5 years)|Median Survival Time, 24 months",,Mingzhi Zhang,Zhengzhou University,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE4,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,hnslblzlzx2011-3,2011-08,2016-04,2016-04,2012-08-14,2016-10-05,2016-10-05,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China",
